UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

NCT03158883 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Avelumab
RADIATION: Stereotactic ablative radiotherapy (SAR)

Sponsor

Megan Daly, MD

Collaborators

[object Object]